Pratap Challa

Pratap Challa


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2009 in Journal of Glaucoma
Verified
Journal Article
Closed access
JSJoshua D. Stein
Joshua D. Stein
AMAllison N. McCoy
Allison N. McCoy
SASanjay Asrani
Sanjay Asrani
LHLeon W. Herndon
Leon W. Herndon
PLPaul P. Md Lee
Paul P. Md Lee
PCPratap Challa
Pratap Challa
Purpose To assess rates of surgical revision of glaucoma drainage devices (GDDs) from hypotony owing to overfiltration and its management. Design Retrospective case series. Methods Demographic characteristics, type of GDD implanted, type of surgical revision, and outcomes were obtained from the charts of patients undergoing GDD implantation and ≥1 subsequent GDD revision in 2002 to 2006. All surgical revisions performed owing to hypotony from overfiltration in the absence of a wound leak were identified. Results Of 1292 eyes undergoing GDD implantation, 21 (1.6%) developed hypotony owing to overfiltration requiring surgical revision: 15 eyes of 488 (3.1%) with a Baerveldt implant and 6 of 804 (0.7%) with an Ahmed (P=0.002). When including primary and secondary revisions, 6 of 12 eyes (50%) treated by using polyglactin suture ligation were successful (did not require additional surgery) compared with 8 of 10 (80%) undergoing suture ligation using prolene. Conclusions Hypotony owing to overfiltration is an uncommon GDD-surgery complication. Understanding how to manage patients who develop this complication can improve patient outcomes.

7 October 2013 in Expert Opinion on Investigational Drugs
Verified
Journal Article
Closed access
PCPratap Challa
Pratap Challa
JAJohn J Arnold
John J Arnold
Introduction: Primary open-angle glaucoma (POAG) is a leading cause for worldwide blindness and is characterized by progressive optic nerve damage. The etiology of POAG is unknown, but elevated intraocular pressure (IOP) and advanced age have been identified as risk factors. IOP reduction is the only known treatment for glaucoma. Recently, drugs that inhibit rho-associated protein kinase (ROCK) have been studied in animals and people for their ability to lower IOP and potentially treat POAG. ROCK inhibitors lower IOP through a trabecular mechanism and may represent a new therapeutic paradigm for the treatment of POAG. Areas covered: Exploring the place that ROCK inhibitors may occupy in our treatment of POAG requires a thorough understanding of pathophysiology and treatment. This article summarizes current research on the incidence, proposed etiologies and mechanisms of action for this drug class. ROCK inhibitor research is presented and considered in light of the current standard of pharmacologic care. Expert opinion: ROCK inhibitors alter the cell shape and extracellular matrix (ECM) of the trabecular meshwork. Preclinical studies demonstrate that these drugs have the potential to become a new therapy for glaucoma. However, ROCK inhibitors can affect multiple cell types, and their utility can be proven only after clinical studies in patients.

1 December 2007 in Journal of Glaucoma
Verified
Journal Article
Closed access
JSJoshua D. Stein
Joshua D. Stein
LHLeon W. Herndon
Leon W. Herndon
JBJ. Brent Bond
J. Brent Bond
PCPratap Challa
Pratap Challa
Purpose To report a series of cases involving Ex-PRESS Miniature Glaucoma Device exposure and discuss the surgical techniques we used to remove the shunts. Methods A retrospective chart review was performed to identify all patients who were referred for Ex-PRESS Miniature Glaucoma Device exposure between January 2004 and December 2005. Demographic information, time to exposure, surgical technique for device implantation and removal, and patient outcomes after device removal were abstracted from the identified charts. In addition, we describe a surgical technique used to remove the exposed Ex-PRESS Miniature Glaucoma Devices. Results Six patients (8 eyes) experienced Ex-PRESS Miniature Glaucoma Device exposure. The average time to exposure was 8.5 months. In 2 eyes, the shunt had been inserted under a half-thickness scleral flap; in both these eyes and 1 additional eye, Mitomycin-C had been used during shunt insertion. At presentation with tube shunt exposure, all eyes had normal or elevated intraocular pressure. In 5 eyes, visual acuity worsened after the device was removed. All 8 patients required concomitant glaucoma surgery with device removal. Conclusions As an increasing number of patients undergo filtration surgery with Ex-PRESS Miniature Glaucoma Devices, anterior segment surgeons should be aware of the potential for device exposure and methods for device removal.

1 December 2013 in Ophthalmology
Verified
Journal Article
Closed access
SOSally Ong
Sally Ong
KSKrishna Sanka
Krishna Sanka
PMPriyatham S. Mettu
Priyatham S. Mettu
TBThomas M. Brosnan
Thomas M. Brosnan
SSSandra S. Stinnett
Sandra S. Stinnett
PCPratap Challa
Pratap Challa

29 January 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
RMRupalatha Maddala
Rupalatha Maddala
LHLeona T. Y. Ho
Leona T. Y. Ho
SKShruthi Karnam
Shruthi Karnam
INIris Navarro
Iris Navarro
AOAnja Osterwald
Anja Osterwald
PRPonugoti Vasantha Rao
Ponugoti Vasantha Rao
Dysregulated levels of growth/differentiation factor-15 (GDF15), a divergent member of the transforming growth factor-beta super family, have been found to be associated with the pathology of various diseases. In this study, we evaluated the levels of GDF15 in aqueous humor (AH) and serum samples derived from primary open-angle glaucoma (POAG) and age- and gender-matched non-glaucoma (cataract) patients to assess the plausible association between GDF15 and POAG. GDF15 levels were determined using an enzyme-linked immunosorbent assay, and data analysis was performed using the Wilcoxon rank sum test, or the Kruskal–Wallis test and linear regression. GDF15 levels in the AH (n = 105) of POAG patients were significantly elevated (by 7.4-fold) compared to cataract patients (n = 117). Serum samples obtained from a subgroup of POAG patients (n = 41) also showed a significant increase in GDF15 levels (by 50%) compared to cataract patients. GDF15 levels were elevated in male, female, African American, and Caucasian POAG patients. This study reveals a significant and marked elevation of GDF15 levels in the AH of POAG patients compared to non-glaucoma cataract control patients. Although serum GDF15 levels were also elevated in POAG patients, the magnitude of difference was much smaller relative to that found in the AH.

30 October 2024 in JCI Insight
Verified
Journal Article
Open access
PDF file
RMRupalatha Maddala
Rupalatha Maddala
PGPallavi Gorijavolu
Pallavi Gorijavolu
LLLevi K. Lankford
Levi K. Lankford
NSNikolai P. Skiba
Nikolai P. Skiba
PCPratap Challa
Pratap Challa
PRPonugoti Vasantha Rao
Ponugoti Vasantha Rao
Ocular hypertension, believed to result partly from increased contractile activity, cell adhesive interactions, and stiffness within the trabecular meshwork (TM), is a major risk factor for glaucoma, a leading cause of blindness. However, the identity of molecular mechanisms governing organization of actomyosin and cell adhesive interactions in the TM remains limited. Based on our previous findings, in which proteomics analyses revealed elevated levels of septins, including septin-9 in human TM cells treated with the ocular hypertensive agent dexamethasone, here, we evaluated the effects of septin-9 overexpression, deficiency, and pharmacological targeting in TM cells. These studies demonstrated a profound impact on actomyosin organization, cell adhesion, contraction, and phagocytosis. Overexpression raised intraocular pressure (IOP) in mice, while inhibition increased cell permeability. In addition, we replicated a significant association between a common variant (rs9038) in SEPT9 with IOP in the Genetic Epidemiology Research on Adult Healthy and Aging (GERA) cohort. Collectively, these data reveal a link between dysregulated septin cytoskeletal organization in the TM and increased IOP, likely due to enhanced cell contraction, adhesive interactions, and fibrotic activity. This suggests that targeting the septin cytoskeleton could offer a novel approach for lowering IOP in patients with glaucoma.